{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:30:21Z","timestamp":1783708221735,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jiac.2022.10.006","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T01:49:45Z","timestamp":1666144185000},"page":"136-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hepatobiliary calculi associated with ceftriaxone treatment: An analysis of FAERS data from 2004 to 2021"],"prefix":"10.1016","volume":"29","author":[{"given":"Xin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juman","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanpeng","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuojing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenfang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jiac.2022.10.006_bib1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00003495-198427060-00001","article-title":"Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use","volume":"27","author":"Richards","year":"1984","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.jiac.2022.10.006_bib2","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/0016-5085(91)90667-A","article-title":"Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate","volume":"100","author":"Park","year":"1991","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jiac.2022.10.006_bib3","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/00006454-198611000-00026","article-title":"Transient formation of precipitations in the gallbladder associated with ceftriaxone therapy","volume":"5","author":"Schaad","year":"1986","journal-title":"Pediatr Infect Dis"},{"key":"10.1016\/j.jiac.2022.10.006_bib4","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0140-6736(88)90596-X","article-title":"Reversible ceftriaxone-associated biliary pseudolithiasis in children","volume":"2","author":"Schaad","year":"1988","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jiac.2022.10.006_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1620\/tjem.211.285","article-title":"Pseudolithiasis due to ceftriaxone treatment for meningitis in children: report of 8 cases","volume":"211","author":"Araz","year":"2007","journal-title":"Tohoku J Exp Med"},{"issue":"6","key":"10.1016\/j.jiac.2022.10.006_bib6","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1055\/s-2008-1072393","article-title":"Early biliary pseudolithiasis during ceftriaxone therapy for acute pyelonephritis in children: a prospective study in 34 children","volume":"10","author":"Bonnet","year":"2000","journal-title":"Eur J Pediatr Surg"},{"issue":"5","key":"10.1016\/j.jiac.2022.10.006_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1055\/s-2008-1072277","article-title":"Biliary pseudolithiasis in childhood: a case report","volume":"9","author":"Herek","year":"1999","journal-title":"Eur J Pediatr Surg"},{"key":"10.1016\/j.jiac.2022.10.006_bib8","first-page":"499","article-title":"[a case report of reversible biliary pseudolithiasis caused by ceftriaxone in childhood: does the problem deserve greater attention?]","volume":"49","author":"Parisi","year":"1997","journal-title":"Minerva Pediatr"},{"issue":"5","key":"10.1016\/j.jiac.2022.10.006_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/jcu.20228","article-title":"Ceftriaxone-associated biliary pseudolithiasis in children","volume":"34","author":"Biner","year":"2006","journal-title":"J Clin Ultrasound"},{"issue":"12","key":"10.1016\/j.jiac.2022.10.006_bib10","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jiac.2019.05.020","article-title":"Experimental verification of factors influencing calcium salt formation based on a survey of the development of ceftriaxone-induced gallstone-related disorder","volume":"25","author":"Ito","year":"2019","journal-title":"J Infect Chemother"},{"issue":"6","key":"10.1016\/j.jiac.2022.10.006_bib11","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1128\/AAC.34.6.1146","article-title":"Apparent biliary pseudolithiasis during ceftriaxone therapy","volume":"34","author":"Heim-Duthoy","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jiac.2022.10.006_bib12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10157-017-1493-7","article-title":"Risk factors of ceftriaxone-associated biliary pseudolithiasis in adults: influence of renal dysfunction","volume":"22","author":"Imafuku","year":"2018","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"10.1016\/j.jiac.2022.10.006_bib13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"10.1016\/j.jiac.2022.10.006_bib14","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/0895-4356(92)90158-J","article-title":"Serum sickness-like reactions to cefaclor","volume":"45","author":"Stricker","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.jiac.2022.10.006_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jiac.2022.10.006_bib16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous adr reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.jiac.2022.10.006_bib17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/pds.964","article-title":"Comparison of data mining methodologies using Japanese spontaneous reports","volume":"13","author":"Kubota","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jiac.2022.10.006_bib18","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2165\/00002018-200629100-00005","article-title":"Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department","volume":"29","author":"Almenoff","year":"2006","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.jiac.2022.10.006_bib19","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1177\/147323001003800614","article-title":"Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in Chinese children","volume":"38","author":"Meng","year":"2010","journal-title":"J Int Med Res"},{"issue":"4","key":"10.1016\/j.jiac.2022.10.006_bib20","first-page":"404","article-title":"Biliary precipitation during ceftriaxone therapy: frequency and risk factors","volume":"49","author":"Soysal","year":"2007","journal-title":"Turk J Pediatr"},{"issue":"3","key":"10.1016\/j.jiac.2022.10.006_bib21","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1442-200x.2004.01900.x","article-title":"Ceftriaxone-induced biliary pseudolithiasis and urinary bladder sludge","volume":"46","author":"Acun","year":"2004","journal-title":"Pediatr Int"},{"key":"10.1016\/j.jiac.2022.10.006_bib22","doi-asserted-by":"crossref","DOI":"10.3747\/pdi.2010.00092","article-title":"Ceftriaxone-associated gallbladder pseudolithiasis in a Pd patient","volume":"31","author":"Rivera","year":"2011","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.jiac.2022.10.006_bib23","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3835825","article-title":"Usefulness of endoscopic managements in patients with ceftriaxone-induced pseudolithiasis causing biliary obstruction","author":"Doi","year":"2017","journal-title":"Case Rep Med"},{"issue":"6","key":"10.1016\/j.jiac.2022.10.006_bib24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4174\/jkss.2011.81.6.423","article-title":"Gallbladder pseudolithiasis caused by ceftriaxone in young adult","volume":"81","author":"Choi","year":"2011","journal-title":"J Korean Surg Soc"},{"issue":"23","key":"10.1016\/j.jiac.2022.10.006_bib25","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.2169\/internalmedicine.8826-17","article-title":"Progressive pseudolithiasis associated with the intravenous administration of ceftriaxone in patients with central nervous system infections","volume":"56","author":"Tsukagoshi","year":"2017","journal-title":"Intern Med"},{"issue":"3","key":"10.1016\/j.jiac.2022.10.006_bib26","first-page":"202","article-title":"Acute cholecystitis and pancreatitis in a patient with biliary sludge associated with the use of ceftriaxone: a rare but potentially severe complication","volume":"14","author":"Famularo","year":"1999","journal-title":"Ann Ital Med Int"},{"key":"10.1016\/j.jiac.2022.10.006_bib27","first-page":"569","article-title":"Acute pancreatitis associated with the administration of ceftriaxone in an adult patient","volume":"106","author":"Sasaki","year":"2009","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"issue":"6","key":"10.1016\/j.jiac.2022.10.006_bib28","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s00383-006-1656-1","article-title":"Acute necrotizing cholecystitis: a rare complication of ceftriaxone-associated pseudolithiasis","volume":"22","author":"Kim","year":"2006","journal-title":"Pediatr Surg Int"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22002896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22002896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:04:59Z","timestamp":1761159899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X22002896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1341321X22002896"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2022.10.006","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatobiliary calculi associated with ceftriaxone treatment: An analysis of FAERS data from 2004 to 2021","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2022.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}